Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120175 | 0.87 | SIGMAR1 (0.54) | FKBP1A | |
| SCHEMBL17913827 | 0.87 | FKBP1A (0.47) | FKBP1ALTA4HMAPTALDH1A1CYP3A4 | |
| SCHEMBL17919877 | 0.87 | FKBP1A (0.47) | FKBP1ALTA4H | |
| SCHEMBL24938939 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL5368566 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL19853295 | 0.86 | ALDH1A1 (0.47) | FKBP1ALTA4HMAPTTRPM8KDM4E | |
| SCHEMBL15325590 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL4249938 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL19408855 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL2818883 | 0.86 | CYP3A4 (0.50) | FKBP1AMAPTKDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1685102-A4 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | FKBP1A 2576/4885LTA4H 1038/4885MAPT 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.